Medvi vs Remedy Meds: A GLP-1 Program Comparison

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This PlexusDx Education Hub comparison sets two GLP-1 telehealth programs side by side so you can see how they actually differ. Browse all Peptides & GLP-1 education

Full head-to-head: PlexusDx vs MEDVi →

Full head-to-head: PlexusDx vs Remedy Meds →

This is an independent editorial comparison. PlexusDx has no commercial relationship with Medvi or Remedy Meds, uses no affiliate links, and was not compensated by either brand.

Medvi and Remedy Meds are two of many programs in the crowded GLP-1 telehealth market. This piece focuses only on the pair named in the query, comparing structure, pricing, and the genetic variable neither addresses. Figures are dated as captured and should be verified directly.

Two programs, two business models

Both brands operate on a telehealth-plus-compounded-pharmacy foundation, yet they package the experience differently. The pharmacology they deliver is identical at the compound level; what separates them is how each structures its offering, prices its plans, and presents those prices to a prospective patient.

Inside Medvi's offering

Medvi's main program dispenses compounded semaglutide and tirzepatide as a weekly injection, plus a dissolvable GLP-1 tablet, through licensed compounding pharmacy pathways. Separately, it offers brand-name Wegovy and Zepbound at a $99 membership plus medication cost. See Medvi's official website for current program details.

Inside Remedy Meds' offering

Remedy Meds also operates as telehealth plus compounded pharmacy, but it publishes far less up front. Its program structures, medication options, and prices are disclosed largely after intake rather than on the marketing page. Consult Remedy Meds's official website for current details as of the date you read this.

Comparing how each one prices

The pricing philosophies diverge sharply. Medvi leads with an ongoing monthly rate, $299 per month for compounded semaglutide and $399 per month for compounded tirzepatide (as captured July 2026), with no membership fee on the compounded program. Remedy Meds publishes no public prices; a rate appears only after its intake quiz, and the only tier captured is a microdose at $189 per month (July 2026). For an apples-to-apples microdose comparison, the PlexusDx Microdose GLP-1 Protocol runs $129 per month flat. Verify current pricing on each brand's own site before deciding.

Same pharmacology, different packaging

Whichever program you weigh, the underlying compound class does the work. GLP-1 receptor agonists such as semaglutide and GIP/GLP-1 dual agonists such as tirzepatide carry extensive trial evidence, including STEP for semaglutide (NEJM 2021), SURMOUNT for tirzepatide (NEJM 2022), and SURMOUNT-OSA for obstructive sleep apnea (NEJM 2024). Effect sizes vary by compound, dose, and population; the brand delivering it does not change the pharmacology.

The variable neither brand measures

Neither Medvi nor Remedy Meds accounts for the upstream genetic architecture shaping every GLP-1 response. Variants in FTO, GLP1R (the receptor every GLP-1 compound targets), MC4R, and TCF7L2 map the baseline metabolic terrain at the pathway level. They do not predict response to any specific compound, but they describe the biology a clinician prescribes into. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights.

Where PlexusDx sits in the comparison

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols and adds the upstream genetic layer neither Medvi nor Remedy Meds includes. The differentiator is pathway-level insight that maps FTO, MC4R variants, context most telehealth programs do not provide alongside the medication.

Not affiliated: PlexusDx has no ownership, partnership, or commercial relationship with Medvi, Remedy Meds, or any brand referenced here.

Related reading: GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs, and GLP 1 Hormone.

Frequently Asked Questions About Medvi and Remedy Meds

Is Medvi better than Remedy Meds?

Neither is objectively better; both operate in the GLP-1 telehealth space with comparable models. They differ in medication options, pricing transparency, and how prices are disclosed. Medvi publishes ongoing rates openly, while Remedy Meds reveals pricing after intake. Individual fit depends on cost, coverage, and program mechanics.

How do the two differ on pricing transparency?

Medvi leads with ongoing published rates, and its compounded program carries no membership fee. Remedy Meds publishes no public prices, showing a rate only after its intake quiz. If seeing a number before committing matters to you, that difference is meaningful.

Do Medvi and Remedy Meds use the same medications?

Both can provide GLP-1 receptor agonists through telehealth, including compounded semaglutide and tirzepatide, and Medvi additionally lists branded Wegovy and Zepbound. The underlying pharmacology is driven by the compound itself, not by the platform dispensing it, so mechanism does not differ by brand.

How does PlexusDx compare to Medvi and Remedy Meds?

PlexusDx offers semaglutide and tirzepatide with upstream genetic context via the Precision Peptide Genetic Test, plus a flat $129 monthly Microdose GLP-1 Protocol for comparison. The differentiator is pathway-level genetic insight not offered at Medvi, Remedy Meds, or most GLP-1 telehealth programs.

More comparisons live in the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Editorial note: This independent article is educational. PlexusDx is not affiliated with Medvi or Remedy Meds and offers its own Weight Management Protocols; the Precision Peptide Genetic Test analyzes peptide pathways and does not predict medication response. Consult a qualified healthcare provider before beginning any protocol.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.